NCT06827080: Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer
- State
- Not started
- Phase
- Phase 1 and Phase 2
- People
- 15 planned
- Started
- 11 Feb 2025
- Primary completion
- 1 Dec 2026
- Arms
- 161Tb-NY032
- Results
- None posted
- 14 Feb 2025: Trial registered